
# IDSA GUIDELINES QUICK START GUIDE

## Overview
The Infectious Diseases Society of America (IDSA) guidelines have been integrated into the Medical Expert Chatbot. This guide provides quick reference for using and testing the IDSA guidelines.

---

## Quick Test Queries

### 1. Community-Acquired Pneumonia (CAP)
```
"What are the IDSA guidelines for community-acquired pneumonia?"
"IDSA CAP guideline"
"IDSA recommendations for pneumonia treatment"
```

**Expected**: IDSA CAP guideline with CURB-65 scoring, antibiotic selection, and duration

---

### 2. Healthcare-Associated Pneumonia
```
"What are the IDSA guidelines for ventilator-associated pneumonia?"
"IDSA HAP VAP guideline"
"IDSA recommendations for hospital-acquired pneumonia"
```

**Expected**: IDSA HAP/VAP guideline with MDR pathogen coverage and prevention strategies

---

### 3. Skin and Soft Tissue Infections
```
"What are the IDSA guidelines for cellulitis?"
"IDSA SSTI guideline"
"IDSA recommendations for skin infections"
```

**Expected**: IDSA SSTI guideline with I&D recommendations and MRSA coverage

---

### 4. Urinary Tract Infections
```
"What are the IDSA guidelines for UTI?"
"IDSA urinary tract infection guideline"
"IDSA recommendations for cystitis"
```

**Expected**: IDSA UTI guideline with first-line agents and duration

---

### 5. Intra-Abdominal Infections
```
"What are the IDSA guidelines for intra-abdominal infections?"
"IDSA IAI guideline"
"IDSA recommendations for peritonitis"
```

**Expected**: IDSA IAI guideline with source control and antibiotic selection

---

### 6. Infective Endocarditis
```
"What are the IDSA guidelines for infective endocarditis?"
"IDSA endocarditis guideline"
"IDSA recommendations for bacterial endocarditis"
```

**Expected**: IDSA IE guideline with Modified Duke Criteria, blood cultures, and antibiotic regimens

---

### 7. Clostridioides difficile Infection
```
"What are the IDSA guidelines for C. diff?"
"IDSA C. difficile guideline"
"IDSA recommendations for Clostridioides difficile"
```

**Expected**: IDSA CDI guideline with severity stratification, vancomycin/fidaxomicin, and FMT

---

### 8. Sepsis and Septic Shock
```
"What are the IDSA guidelines for sepsis?"
"IDSA sepsis guideline"
"Surviving Sepsis Campaign guidelines"
```

**Expected**: IDSA/SCCM sepsis guideline with Hour 1 Bundle, fluid resuscitation, and vasopressors

---

## Key Features

### Recommendation Strength
- **Strong (A)**: High quality evidence, clear benefit
- **Moderate (B)**: Moderate quality evidence, likely benefit
- **Weak (C)**: Low quality evidence, possible benefit

### Quality of Evidence
- **High (I)**: Well-designed RCTs or meta-analyses
- **Moderate (II)**: Well-designed observational studies
- **Low (III)**: Case series, case reports, expert opinion

### Clinical Implementation
Each guideline includes:
- Comprehensive clinical implementation guidance
- Specific antibiotic regimens with dosing
- Duration of therapy
- Monitoring recommendations
- Complications management

---

## Guidelines Included (8 Total)

### 1. Community-Acquired Pneumonia (CAP)
- **Topics**: Severity assessment, outpatient vs. inpatient management, antibiotic selection
- **Key Points**: CURB-65, PSI, 5-7 day duration, vaccination
- **Recommendations**: 8 Strong, 7 Moderate, 3 Weak

### 2. Healthcare-Associated Pneumonia (HAP/VAP)
- **Topics**: Diagnosis, MDR pathogens, empiric therapy, prevention
- **Key Points**: Culture collection, MRSA/Pseudomonas coverage, 7-day duration, ventilator bundle
- **Recommendations**: 7 Strong, 6 Moderate, 3 Weak

### 3. Skin and Soft Tissue Infections (SSTI)
- **Topics**: Classification, I&D, MRSA coverage, necrotizing infections
- **Key Points**: I&D for abscesses, 5-7 day duration, emergent debridement for necrotizing fasciitis
- **Recommendations**: 6 Strong, 6 Moderate, 3 Weak

### 4. Urinary Tract Infections (UTI)
- **Topics**: Uncomplicated vs. complicated, first-line agents, pyelonephritis
- **Key Points**: Nitrofurantoin/TMP-SMX/fosfomycin, 3-5 day duration, avoid asymptomatic bacteriuria treatment
- **Recommendations**: 6 Strong, 5 Moderate, 3 Weak

### 5. Intra-Abdominal Infections (IAI)
- **Topics**: Source control, community vs. healthcare-associated, specific infections
- **Key Points**: Source control essential, 4-7 day duration, broad-spectrum for healthcare-associated
- **Recommendations**: 6 Strong, 5 Moderate, 3 Weak

### 6. Infective Endocarditis
- **Topics**: Modified Duke Criteria, blood cultures, echocardiography, pathogen-specific therapy
- **Key Points**: 3 blood culture sets, TEE for prosthetic valves, 4-6 week IV antibiotics, surgical indications
- **Recommendations**: 7 Strong, 5 Moderate, 3 Weak

### 7. Clostridioides difficile Infection
- **Topics**: Diagnostic testing, severity stratification, treatment, recurrence management
- **Key Points**: NAAT for diagnosis, vancomycin/fidaxomicin, FMT for recurrent CDI, bezlotoxumab
- **Recommendations**: 7 Strong, 6 Moderate, 3 Weak

### 8. Sepsis and Septic Shock
- **Topics**: Recognition, Hour 1 Bundle, fluid resuscitation, vasopressors, source control
- **Key Points**: SOFA score, antibiotics within 1 hour, 30 mL/kg fluids, norepinephrine, MAP ≥65 mmHg
- **Recommendations**: 7 Strong, 7 Moderate, 4 Weak

---

## Common Antibiotic Regimens

### Community-Acquired Pneumonia
- **Outpatient (healthy)**: Amoxicillin 1g TID, doxycycline 100mg BID, or azithromycin
- **Outpatient (comorbidities)**: Amoxicillin-clavulanate + macrolide OR levofloxacin
- **Inpatient**: Ceftriaxone + azithromycin OR levofloxacin
- **ICU**: Ceftriaxone + azithromycin OR levofloxacin

### Healthcare-Associated Pneumonia
- **No MDR risk**: Piperacillin-tazobactam, cefepime, or levofloxacin
- **MDR risk**: Antipseudomonal beta-lactam + fluoroquinolone or aminoglycoside
- **MRSA risk**: Add vancomycin or linezolid

### Cellulitis
- **Uncomplicated**: Cephalexin 500mg QID or dicloxacillin 500mg QID
- **Purulent/MRSA**: TMP-SMX DS BID, doxycycline 100mg BID, or clindamycin

### Urinary Tract Infections
- **Uncomplicated cystitis**: Nitrofurantoin 100mg BID × 5 days, TMP-SMX DS BID × 3 days, or fosfomycin 3g × 1
- **Pyelonephritis**: Ciprofloxacin 500mg BID × 5-7 days or levofloxacin 750mg daily × 5-7 days

### Intra-Abdominal Infections
- **Community-acquired**: Ertapenem 1g daily OR ceftriaxone + metronidazole
- **Healthcare-associated**: Piperacillin-tazobactam OR carbapenem

### Infective Endocarditis
- **Viridans streptococci**: Penicillin G or ceftriaxone for 4 weeks
- **MSSA**: Nafcillin or oxacillin for 6 weeks
- **MRSA**: Vancomycin for 6 weeks
- **Enterococci**: Ampicillin + gentamicin for 4-6 weeks

### Clostridioides difficile
- **Non-severe**: Vancomycin 125mg QID or fidaxomicin 200mg BID for 10 days
- **Severe**: Vancomycin 125mg QID for 10 days
- **Fulminant**: Vancomycin 500mg QID + IV metronidazole
- **Recurrent**: Tapered/pulsed vancomycin, fidaxomicin, or FMT

### Sepsis and Septic Shock
- **Empiric**: Vancomycin + piperacillin-tazobactam OR cefepime OR carbapenem
- **Source-specific**: Adjust based on likely source
- **Duration**: 7-10 days after source control

---

## Troubleshooting

### IDSA Guidelines Not Appearing
1. Check if query includes "guideline", "recommendation", "IDSA", or "infectious diseases society"
2. Verify keywords match guideline entry
3. Check console logs for search results
4. Try more specific query (e.g., "IDSA CAP guideline")

### Wrong Guideline Returned
1. Refine query with specific keywords
2. Add "IDSA" to query
3. Use full guideline name
4. Check for keyword overlap with other guidelines

### Content Bleeding
1. Verify guideline attribution in response
2. Check if multiple guidelines returned
3. Ensure clear separation between sources
4. Report issue for keyword refinement

---

## Best Practices

### For Users
1. **Be Specific**: Use "IDSA guideline for [condition]" for best results
2. **Use Keywords**: Include "guideline", "recommendation", or "IDSA"
3. **Check Attribution**: Verify response is from IDSA guidelines
4. **Review Links**: Click IDSA URL for full guideline

### For Developers
1. **Add Keywords**: Include disease-specific and guideline-specific terms
2. **Test Thoroughly**: Run stress tests after adding new guidelines
3. **Monitor Logs**: Check console for search results and scores
4. **Prevent Bleeding**: Use specific keywords to avoid overlap

---

## Future Enhancements

### Short-Term (Next Phase)
- Add more IDSA guidelines (endocarditis, meningitis, sepsis, C. diff)
- Expand antibiotic coverage
- Add drug interaction warnings
- Include allergy-based recommendations

### Medium-Term
- Integrate CDC guidelines
- Add WHO guidelines
- Include NIH HIV/AIDS guidelines
- Add AASLD hepatology guidelines

### Long-Term
- Antibiogram integration
- Guideline comparison tool
- Update notifications
- Regional variations
- Clinical decision support

---

## Support

### Documentation
- **Integration Report**: `PHASE_24_IDSA_COMPLETION.md`
- **Stress Test Suite**: `PHASE_24_IDSA_STRESS_TEST.md`
- **Quick Start**: This document

### Code Files
- **Guidelines**: `data/idsaGuidelinesKnowledge.ts`
- **Chatbot**: `app/(tabs)/(home)/chatbot.tsx`
- **References**: `data/infectiousDiseaseReferences.ts`

### Contact
For issues or questions, refer to the stress test documentation or review console logs for debugging information.

---

## Summary

The IDSA guidelines integration provides comprehensive infectious disease management guidance with evidence-based recommendations. Use the quick test queries above to explore the guidelines and verify functionality. The integration maintains the same high quality as previous guideline integrations and includes robust content bleeding prevention.

**Status**: ✅ READY FOR USE AND TESTING
